David Braunreiter, MD
Sports Medicine · Sugar Land, TXNPI 1972572055
Payments from drug & device makers
Across 7 payments — averaging $55.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$200
- Edwards Lifesciences$66
- Pacira Pharmaceuticals Incorporated$38
- Medinc Of Texas$31
- Abbott$20
- Hydrocision, Inc.$17
- plus $15 from 1 others
Across 3 payments — averaging $7833.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$24K
What the payments were for
- Travel & lodging$6617%
- Food & beverage$32183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 1 | $200 |
| Edwards Lifesciences | 1 | $66 |
| Pacira Pharmaceuticals Incorporated | 1 | $38 |
| Medinc Of Texas | 1 | $31 |
| Abbott | 1 | $20 |
| Hydrocision, Inc. | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $15 |
How this compares
$387 in reported general payments places this provider in the 25th percentile of 437 sports medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $78,688 |
| MounjaroTirzepatide | 44 | $51,588 |
| TrulicityDulaglutide | 38 | $44,257 |
| EliquisApixaban | 47 | $33,344 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $18,522 |
| XareltoRivaroxaban | 16 | $14,733 |
| LivaloPitavastatin Calcium | 13 | $8,994 |
| LinzessLinaclotide | 17 | $8,467 |
| Repatha SureclickEvolocumab | 12 | $6,446 |
| Pitavastatin Calcium | 14 | $3,366 |
| Atorvastatin Calcium | 327 | $2,408 |
| Celecoxib | 103 | $2,354 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 64 | $2,290 |
| Levothyroxine Sodium | 192 | $1,835 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $1,768 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Sugar Land
- Kyle BorqueSugar Land$63K
- Laura LinscheidSugar Land$55K
- Bonnie GregorySugar Land$47K
- Ronak PatelSugar Land$39K
- Timothy VachrisAustin$5.7M
- Thomas DeberardinoSan Antonio$3.5M
- Mark HutchensAustin$2.5M
- Robert ScheinbergDallas$2.2M
- Marc LabbeThe Woodlands$2M
- Walter LoweHouston$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.